SCHEMBL3621092

SCHEMBL3621092

CC(C)(C)[Si](C)(C)OCCN(C#N)c1ccc(NC(=O)c2cnccc2NC(=O)c2ccc(Cl)s2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRSS12 P56730 2/20 0.39
F10 P00742 4/20 0.35
MEN1 O00255 5/20 0.34
KMT2A Q03164 5/20 0.34
KDM4E B2RXH2 4/20 0.34
TSHR P16473 1/20 0.34
USP7 Q93009 1/20 0.33
USP47 Q96K76 1/20 0.33
ALDH1A1 P00352 5/20 0.33
NPC1 O15118 5/20 0.33
RAB9A P51151 5/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
NPSR1 Q6W5P4 2/20 0.33
HPGD P15428 2/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
ROCK2 O75116 1/20 0.32
ROCK1 Q13464 1/20 0.32
HTT P42858 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3617006 0.94 PRSS12 (0.37) PRSS12F10MEN1KMT2AKDM4E
SCHEMBL3618059 0.90 PRSS12 (0.40) PRSS12F10MEN1KMT2AKDM4E
SCHEMBL3622782 0.88 PRSS12 (0.38) PRSS12F10MEN1KMT2AKDM4E
SCHEMBL3608503 0.87 PRSS12 (0.43) PRSS12F10MEN1KMT2AKDM4E
SCHEMBL3619119 0.86 PRSS12 (0.39) PRSS12F10MEN1KMT2AKDM4E
SCHEMBL3609334 0.85 PRSS12 (0.38) PRSS12F10MEN1KMT2AKDM4E
SCHEMBL3621698 0.85 PRSS12 (0.38) PRSS12F10MEN1KMT2AKDM4E
SCHEMBL3623718 0.85 NPC1 (0.37) PRSS12F10MEN1KMT2AKDM4E
SCHEMBL3617278 0.85 KDM4E (0.48) PRSS12F10MEN1KMT2AKDM4E
SCHEMBL3621920 0.85 F10 (0.43) PRSS12F10MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004292-A1 Iminooxazolidine Derivatives and Their Use BAYER HEALTHCARE AG (DE) 2010-01-07 US disclosed
EP-1928868-A1 IMINOOXAZOLIDINE DERIVATIVES AND USE THEREOF Bayer HealthCare AG (DE) 2008-06-11 EP disclosed
WO-2007028520-A1 IMINOOXAZOLIDINE DERIVATIVES AND USE THEREOF BAYER HEALTHCARE AG (DE) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004292-A1 Iminooxazolidine Derivatives and Their Use PPOX, XDH, PNPO PRSS12 3975/4885F10 152/4885MEN1 561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.